In Q1 FY2026 (ended March 31, 2026), Beta Bionics reported revenue of $27.6 million, up 56.6% year-over-year. Net loss was $21.9 million, improving 23.6% from the prior year. Operating loss widened to $24.3 million, while diluted EPS improved to -$0.49. The company held $30.2 million in cash and $271.2 million in equity, with no long-term debt.
•Revenue grew 56.6% YoY to $27.6 million.
•Net loss narrowed 23.6% YoY to $21.9 million.
•Operating loss increased 30.2% YoY to $24.3 million.
•Cash and equivalents stood at $30.2 million; no long-term debt.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Beta Bionics, Inc., a commercial-stage medical device company provides the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older.
The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing. Its portfolio also includes Bihormonal iLet, which combines automated delivery of insulin and glucagon, and iLet to treat people with insulin-dependent type-2 diabetes.
It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation Development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. Incorporated in 2015, the company is headquartered in Irvine, California.
Beta Bionics, Inc. is a commercial-stage medical device company focused on improving the lives of people with insulin-requiring diabetes. The company designs, develops, and commercializes solutions to enhance health and quality of life. Its primary product is the iLet Bionic Pancreas, an insulin delivery device approved for treating type 1 diabetes in adults and children aged six years and older. Beta Bionics is also developing a Patch Pump, an insulin pump that adheres directly to the skin and delivers insulin without tubing. Additionally, the company is working on a Bihormonal iLet that combines automated delivery of both insulin and glucagon, and an iLet system for insulin-dependent type 2 diabetes. Beta Bionics has collaboration agreements with Xeris Pharmaceuticals for a pump-compatible glucagon formulation and with Abbott Diabetes Care for an automated insulin delivery system.
Where is Beta Bionics (BBNX) listed and in which currency?
Beta Bionics, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol BBNX. The company's stock is traded in U.S. dollars (USD), as it is headquartered in the United States. Being listed on a major U.S. exchange provides liquidity and visibility to investors worldwide. The NasdaqGM is a tier of the Nasdaq Stock Market that lists companies meeting certain financial and corporate governance standards. Investors can buy and sell BBNX shares through most brokerage platforms that offer access to U.S. equities.
What sector and industry does Beta Bionics (BBNX) operate in?
Beta Bionics, Inc. operates in the Healthcare sector, specifically within the Medical Devices industry. As a medical device company, it focuses on developing and commercializing products that help manage diabetes, a chronic condition affecting millions worldwide. The Medical Devices industry encompasses a wide range of products, from diagnostic equipment to therapeutic devices like insulin pumps. Beta Bionics' innovative iLet Bionic Pancreas and other pipeline products position it within the subset of diabetes management devices, a rapidly growing field driven by technological advancements and increasing prevalence of diabetes.
Where is Beta Bionics (BBNX) headquartered and what markets does it serve?
Beta Bionics, Inc. is headquartered in Irvine, California, United States. The company was incorporated in 2015 and has since focused on developing solutions for people with insulin-requiring diabetes. While its primary market is the United States, where its products are approved and commercialized, the company's collaborations with global partners like Abbott Diabetes Care and Xeris Pharmaceuticals suggest potential for broader market reach. The iLet Bionic Pancreas is approved for type 1 diabetes in adults and children aged six and older, and the company is also developing products for type 2 diabetes and bihormonal therapy, indicating a commitment to serving diverse patient populations.
What is Beta Bionics' business model and how does it generate revenue?
Beta Bionics generates revenue primarily through the sale of its medical devices and related supplies. Its flagship product, the iLet Bionic Pancreas, is an insulin delivery device that patients purchase, along with ongoing consumables such as insulin cartridges and infusion sets. The company also has collaboration and license agreements that may provide milestone payments and royalties. For instance, Beta Bionics has a collaboration with Xeris Pharmaceuticals to develop a pump-compatible glucagon formulation, and a development and commercialization agreement with Abbott Diabetes Care for an automated insulin delivery system. These partnerships can generate upfront payments, development milestones, and future royalties on product sales. Additionally, the company is developing a Patch Pump and a Bihormonal iLet, which could open new revenue streams upon commercialization.